GlassScriptPhysician profile
Andrew Chapman Taylor
NPI 1467870972
$10,323.19
in general payments reported to CMS, 2019-2025
68 companies · $2,916 in 2025
The $2,916 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $516 · 2021: $1,179 · 2022: $1,347 · 2023: $1,924 · 2024: $2,045 · 2025: $2,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,010 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,009.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,383.54 | 2019-2025 | Ultomiris |
| Sk Life Science, INC. | $1,109.32 | 2020-2025 | Xcopri |
| Lundbeck LLC | $795.60 | 2019-2025 | Vyepti, Rexulti |
| Abbvie INC. | $679.77 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Novartis Pharmaceuticals Corporation | $528.13 | 2019-2025 | |
| Csl Behring | $516.44 | 2019-2025 | Hizentra |
| Pfizer INC. | $478.81 | 2023-2025 | |
| Emd Serono, INC. | $472.07 | 2020-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $268.84 | 2020-2025 | Austedo Xr, Austedo Xr |
| Alnylam Pharmaceuticals INC. | $254.44 | 2019-2025 | Onpattro, Givlaari, Amvuttra |
| Biogen, INC. | $253.75 | 2021-2025 | Tysabri, Vumerity, Plegridy |
| Mallinckrodt Hospital Products INC. | $227.38 | 2020-2025 | Acthar |
| Celgene Corporation | $216.33 | 2021-2024 | Zeposia |
| Amgen INC. | $192.45 | 2022-2025 | Uplizna, Aimovig |
| Eisai INC. | $177.67 | 2021-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $167.05 | 2022-2025 | Rystiggo, Briviact, Zilbrysq |
| Amneal Pharmaceuticals LLC | $151.44 | 2020-2024 | Ongentys, Rytary, Lyvispah |
| Catalyst Pharmaceuticals, INC. | $147.42 | 2021-2025 | Fycompa, Firdapse |
| Xeris Pharmaceuticals, INC. | $144.69 | 2021-2024 | Keveyis |
| Tanabe Pharma America, INC. | $133.86 | 2019-2025 | Radicava |
| Allergan, INC. | $127.58 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $111.35 | 2021 | |
| Edw Pharma, INC. | $108.27 | 2023 | Tiglutik |
| Lilly USA, LLC | $104.14 | 2019-2025 | Amyvid, Kisunla |
| Neurocrine Biosciences, INC. | $87.73 | 2020-2021 | |
| Averitas Pharma INC. | $87.50 | 2023-2025 | Qutenza |
| Tg Therapeutics, INC. | $84.15 | 2023-2025 | |
| Acorda Therapeutics, INC | $74.76 | 2019-2024 | Ampyra, Inbrija |
| Otsuka America Pharmaceutical, INC. | $64.48 | 2024-2025 | Rexulti, Nuedexta |
| Argenx US, INC. | $64.16 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Kedrion Biopharma, INC. | $62.86 | 2024-2025 | Kedrab, Koate, Gammaked |
| Ge Healthcare | $55.76 | 2021-2023 | |
| Medtronic, INC. | $50.89 | 2023 | Intellis Adaptivestim, Percept PC Brainsense |
| Avanir Pharmaceuticals, INC. | $48.19 | 2019 | |
| Acadia Pharmaceuticals INC | $47.88 | 2024 | Nuplazid, Daybue |
| Neuropace, INC. | $45.56 | 2024 | |
| Almatica Pharma LLC | $42.38 | 2021 | |
| Ani Pharmaceuticals, INC. | $41.23 | 2023-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $41.11 | 2024-2025 | Wainua |
| Amylyx Pharmaceuticals, INC. | $40.15 | 2023-2024 | Relyvrio |
| Biohaven Pharmaceutical Holding Company LTD. | $38.25 | 2022 | |
| Merz Pharmaceuticals, LLC | $37.15 | 2021 | |
| Livanova USA, INC. | $36.30 | 2021-2022 | |
| Genentech USA, INC. | $35.47 | 2024 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Grifols USA, LLC | $35.24 | 2022-2025 | Gamunex-C |
| Impel Pharmaceuticals INC. | $35.17 | 2023 | Trudhesa |
| Horizon Therapeutics Plc | $33.44 | 2022-2023 | Uplizna |
| Janssen Biotech, INC. | $33.15 | 2025 | |
| Greenwich Biosciences, INC. | $27.89 | 2020 | |
| Octapharma USA, INC. | $26.80 | 2025 | Panzyga |
| Arbor Pharmaceuticals, INC. | $22.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.55 | 2020 | |
| Genzyme Corporation | $21.71 | 2023 | |
| Mdd US Operations, LLC | $21.12 | 2023 | Apokyn |
| Grt US Holding, INC. | $20.02 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.31 | 2021 | |
| Axsome Therapeutics, INC. | $18.22 | 2023 | Sunosi |
| Mylan Specialty L.P. | $17.49 | 2023 | Glatiramer Acetate |
| Takeda Pharmaceuticals U.S.A., INC. | $17.47 | 2024 | Hyqvia |
| Adamas Pharmaceuticals, INC. | $17.03 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.74 | 2022 | |
| Avion Pharmaceuticals | $14.53 | 2022 | |
| Neurelis, INC. | $14.29 | 2024 | Valtoco |
| Merz North America, INC. | $14.29 | 2020 | |
| Tonix Medicines, INC. | $13.96 | 2025 | Tonmya |
| Sanofi-Aventis U.S. LLC | $13.87 | 2020 | |
| Kyowa Kirin, INC. | $11.72 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.